Based on limited published evidence, VN1R2 is annotated as a putative pheromone receptor localized to the plasma membrane with pheromone binding capability. However, VN1R2's known olfactory function contrasts with its identification in cancer genomics studies. VN1R2 was detected among genomic variations in glioma samples 1 and identified as a joint biomarker across prostate, breast, and ovarian cancers 2, suggesting potential dysregulation in malignancies. The biological significance of VN1R2 alterations in cancer remains unclear.